Payment overview · 2025
General Payments
$759.79
19 reported records · 14 companies
Healthcare provider profile · identity verified
Elizabeth Gernhardt, DO
Allopathic & Osteopathic Physicians|Family Medicine · FORTY FORT, PA · NPI 1972580405
Verified facts
What the public records show
CMS Open Payments records show Elizabeth Gernhardt, DO received $759.79 in general payments during 2025 across 19 reported records.
Medtronic, Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$171.23 | 22.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $137.31 | 18.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $102.06 | 13.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $87.62 | 11.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.08 | 8.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.90 | 3.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.42 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.57 | 3.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.09 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.46 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.49 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.26 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.27 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.03 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $759.79 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $171.23 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $137.31 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $102.06 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.62 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $66.08 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.09 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
122 | 24 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 78 |
| Simvastatin | Simvastatin | 369 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 344 | 72 |
| Losartan Potassium | Losartan Potassium | 292 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 273 | 64 |
| Omeprazole | Omeprazole | 262 | 60 |
| Famotidine | Famotidine | 247 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 52 |
| Gabapentin | Gabapentin | 212 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 47 |
| Lisinopril | Lisinopril | 171 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 30 |
| Metformin Hcl | Metformin Hcl | 148 | 35 |
| Buspirone Hcl | Buspirone Hcl | 146 | 25 |
| Alendronate Sodium | Alendronate Sodium | 140 | 28 |
| Meloxicam | Meloxicam | 133 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 31 |
| Alprazolam | Alprazolam | 127 | 22 |
| Synthroid | Levothyroxine Sodium | 122 | 24 |
| Potassium Chloride | Potassium Chloride | 120 | 22 |
| Allopurinol | Allopurinol | 116 | 23 |
| Montelukast Sodium | Montelukast Sodium | 110 | 22 |
| Enalapril Maleate | Enalapril Maleate | 109 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 27 |
| Furosemide | Furosemide | 102 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 12 |
| Eliquis | Apixaban | 83 | 20 |
| Glimepiride | Glimepiride | 83 | 20 |
| Metformin Hcl Er | Metformin Hcl | 80 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 37 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 74 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 20 |
| Ozempic | Semaglutide | 73 | 12 |
| Torsemide | Torsemide | 73 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 13 |
| Warfarin Sodium | Warfarin Sodium | 65 | 15 |
| Sertraline Hcl | Sertraline Hcl | 64 | 16 |
| Trazodone Hcl | Trazodone Hcl | 63 | 13 |
| Atenolol | Atenolol | 62 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | suppressed |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Methylprednisolone | Methylprednisolone | 55 | 50 |
| Ramipril | Ramipril | 52 | suppressed |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Bumetanide | Bumetanide | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 13 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 14 |
| Azithromycin | Azithromycin | 44 | 32 |
| Celecoxib | Celecoxib | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 11 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 23 |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Cefadroxil | Cefadroxil | 16 | 15 |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Dilantin | Phenytoin Sodium Extended | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Nitroglycerin Patch | Nitroglycerin | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $759.79 · 19 records | Medtronic, Inc. | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, General - Pain Management, Kerendia, MOUNJARO, PREVNAR 20, SYMPLICITY G3, SYNTHROID, Sunosi, UBRELVY, VOQUEZNA, Veozah, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error